Evaluation of the effect of prostate volume change on tumor control probability in LDR brachytherapy

Journal of Contemporary Brachytherapy

Volumn 3, Issue 3, 2011, Pages 125-130

  Knaup, Courtney ^a   Mavroidis, Panayiotis ^b   Stathakis, Sotirios ^a   Smith, Mark ^a   Swanson, Gregory ^a   Papanikolaou, Niko ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Brachytherapy; LDR; Prostate cancer; Radiation biology

Indexed keywords

PALLADIUM 103; RADIOACTIVE SEED;

ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; HUMAN; LOW ENERGY RADIATION; MALE; ORGAN SIZE; PROSTATE CANCER; RADIATION DOSE; RADIOBIOLOGY; RELATIVE BIOLOGIC EFFECTIVENESS; TUMOR CONTROL PROBABILITY;

EID: 80053457474     PISSN: 1689832X     EISSN: None     Source Type: Journal    
DOI: 10.5114/jcb.2011.24818     Document Type: Article

References (40)

1. Prostate Cancer Overview 2010 [cited 2010 12/06]; Available from: http://www.cancer.org/Cancer/ProstateCancer/OverviewGuide/prostate-cancer- overview-key-statistics.
2. Wang JZ, Mayr NA, Nag S et al. Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapy. Med Phys 2006; 4: 1025-1032.
3. Dogan N, Mohideen N, Glasgow GP et al. Effect of prostatic edema on CT-based postimplant dosimetry. Int J Radiat Oncol Biol Phys 2002; 2: 483-489. (Pubitemid 34522114)
4. Ling CC. Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1992; 1: 81-87.
5. Nag S, Scaperoth DD, Badalament R et al. Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration. Urology 1995; 1: 87-92.
6. Nag S, Beyer D, Friedland J et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 4: 789-799. (Pubitemid 29284127)
7. Beyer D, Nath R, Butler Wet al. American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The clinical research committee of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2000; 2: 273-275. (Pubitemid 30236365)
8. Dale RG. Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model. BJR 1989; 735: 241-244. (Pubitemid 19064266)
9. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. BJR 1985; 690: 515-528. (Pubitemid 15018411)
10. Jones B, Dale RG, Gaya AM. Linear quadratic modeling of increased late normal-tissue effects in special clinical situations. Int J Radiat Oncol Biol Phys 2006; 3: 948-953. (Pubitemid 43183598)
11. Zaider M, Hanin L. Biologically-equivalent dose and long-term survival time in radiation treatments. Phys Med Biol 2007; 20: 6355-6362. (Pubitemid 350093198)
12. Kim Y, Tome WA. Risk-adaptive optimization: selective boosting of high-risk tumor subvolumes. Int J Radiat Oncol Biol Phys 2006; 5: 1528-1542.
13. Yu Y, Anderson LL, Li Z et al. Permanent prostate seed implant brachytherapy: report of the American Association of Physicists in Medicine Task Group No. 64. Med Phys 1999; 10: 2054- 2076.
14. Nag S, Bice W, DeWyngaert K et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000; 1: 221-230. (Pubitemid 30021503)
15. Waterman FM, Yue N, Corn BW et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on postimplant dosimetry: an analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 1998; 5: 1069-1077. (Pubitemid 28377488)
16. Crook J, McLean M, Yeung I et al. MRI-CT fusion to assess postbrachytherapy prostate volume and the effects of prolonged edema on dosimetry following transperineal interstitial permanent prostate brachytherapy. Brachytherapy 2004; 2: 55-60. (Pubitemid 39221348)
17. Mavroidis P, Lind BK, Brahme A. Biologically effective uniform dose (D) for specification, report and comparison of dose response relations and treatment plans. Phys Med Biol 2001; 10: 2607-2630. (Pubitemid 32982398)
18. Millar WT. Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy. BJR 1991; 759: 242-251.
19. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001; 4: 1021-1031. (Pubitemid 32594841)
20. King CR, Fowler JF. A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys 2001; 1: 213-214. (Pubitemid 32758881)
21. Wang JZ, Guerrero M, Li XA. How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 2003; 1: 194-203. (Pubitemid 36020360)
22. Brenner DJ. Hypofractionation for prostate cancer radiotherapy - what are the issues? Int J Radiat Oncol Biol Phys 2003; 4: 912-914. (Pubitemid 37324108)
23. Carlson DJ, Stewart RD, Li XA et al. Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer. Phys Med Biol 2004; 19: 4477-4491. (Pubitemid 39378241)
24. Antipas V, Dale RG, Coles IP. A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of 125I and 103Pd. Phys Med Biol 2001; 10: 2557-2569. (Pubitemid 32982395)
25. Armpilia CI, Dale RG, Coles IP et al. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys 2003; 2: 378-385. (Pubitemid 36069096)
26. Wuu CS, Zaider M. A calculation of the relative biological effectiveness of 125I and 103Pd brachytherapy sources usingthe concept of proximity function. Med Phys 1998; 11: 2186-2189. (Pubitemid 28530108)
27. Ling CC, Li WX, Anderson LL. The relative biological effectiveness of I-125 and Pd-103. Int J Radiat Oncol Biol Phys 1995; 2: 373-378.
28. Nahum AE, Movsas B, Horwitz EM et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 2003; 2: 391-401. (Pubitemid 37040935)
29. Kallman P, Agren A, Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Oncol Biol Phys 1992; 2: 249-262.
30. Nath R, Bice WS, Butler WM et al. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137. Med Phys 2009; 11: 5310-5322.
31. Mavroidis P, Ferreira BC, Shi C et al. Treatment plan comparison between helical tomotherapy and MLC-based IMRT using radiobiological measures. Phys Med Biol 2007; 13: 3817-3836. (Pubitemid 46908597)
32. Ferreira BC, Mavroidis P, Adamus-Gorka M et al. The impact of different dose-response parameters on biologically optimized IMRT in breast cancer. Phys Med Biol 2008; 10: 2733-2752.
33. Mavroidis P, Laurell G, Kraepelien T et al. Determination and clinical verification of dose-response parameters for esophageal stricture from head and neck radiotherapy. Acta Oncol 2003; 8: 865-881. (Pubitemid 38091187)
34. Mavroidis P, al-Abany M, Helgason AR et al. Dose-response relations for anal sphincter regarding fecal leakage and blood or phlegm in stools after radiotherapy for prostate cancer. Radiobiological study of 65 consecutive patients. Strahlenther Onkol 2005; 5: 293-306. (Pubitemid 40768419)
35. Strigari L, Orlandini LC, Andriani I et al. A mathematical approach for evaluating the influence of dose heterogeneity on TCP for prostate cancer brachytherapy treatment. Phys Med Biol 2008; 18: 5045-5059.
36. Li XA, Wang JZ, Stewart RD et al. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations. Phys Med Biol 2003; 17: 2753-2765. (Pubitemid 37121458)
37. Haworth A, Ebert M, Waterhouse D et al. Assessment of i-125 prostate implants by tumor bioeffect. Int J Radiat Oncol Biol Phys 2004; 5: 1405-1413. (Pubitemid 38954062)
38. Badiozamani KR, Wallner K, Sutlief S et al. Anticipating prostatic volume changes due to prostate brachytherapy. Radiat Oncol Invest 1999; 6: 360-364. (Pubitemid 30033355)
39. Potters L, Cao Y, Calugaru E et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001; 3: 605-614. (Pubitemid 32519593)
40. Blasko JC, Grimm PD, Sylvester JE et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys hysics 2000; 4: 839-850.